James Winston, MD
Psychiatry · Milwaukee, WINPI 1124111893
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (48.2%), consulting fees and education — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Corium, LLC at 40.9% of the total. Reporting peaked in 2024 at $2,979 and has fallen 84.0% since, to $476 in 2025. Among psychiatry clinicians in WI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 187 payments — averaging $35.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corium, LLC$3K
- Teva Pharmaceuticals USA, Inc.$837
- Johnson & Johnson$540
- Otsuka America Pharmaceutical, Inc.$332
- Treace Medical Concepts, Inc.$303
- Shire North American Group Inc$303
- plus $2K from 17 others
What the payments were for
- Consulting fees$2,64040%
- Travel & lodging$501%
- Food & beverage$3,21148%
- Education$75711%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Corium, LLC | 5 | $2,725 |
| Teva Pharmaceuticals USA, Inc. | 18 | $837 |
| Johnson & Johnson | 24 | $540 |
| Otsuka America Pharmaceutical, Inc. | 7 | $332 |
| Treace Medical Concepts, Inc. | 4 | $303 |
| Shire North American Group Inc | 22 | $303 |
| Lundbeck LLC | 15 | $218 |
| Harmony Biosciences LLC | 12 | $211 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $206 |
| Sunovion Pharmaceuticals Inc. | 12 | $176 |
| Avanir Pharmaceuticals, Inc. | 7 | $159 |
| AbbVie | 7 | $99 |
| Adlon Therapeutics L.p. | 6 | $85 |
| Ironshore Pharmaceuticals Inc. | 5 | $79 |
| OWP Pharmaceuticals, Inc. | 6 | $76 |
| Jazz Pharmaceuticals Inc. | 5 | $75 |
| Neos Therapeutics, LP | 5 | $72 |
| Almatica Pharma LLC | 2 | $45 |
| Bausch Health US, LLC | 3 | $38 |
| Vertical Pharmaceuticals, LLC | 2 | $25 |
| Biogen | 1 | $25 |
| Orexo US, Inc. | 1 | $15 |
| Vanda Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Azstarys$2,640
- REXULTI$232
- SPRAVATO$230
- Lapiplasty System$157
How this compares
$6,658 in reported general payments places this provider in the 90th percentile of 543 psychiatry providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 12 | $101,349 |
| VraylarCariprazine Hcl | 26 | $39,349 |
| VyvanseLisdexamfetamine Dimesylate | 53 | $25,217 |
| Lurasidone Hcl | 60 | $13,811 |
| TrintellixVortioxetine Hydrobromide | 22 | $12,489 |
| Lisdexamfetamine Dimesylate | 34 | $8,233 |
| Divalproex Sodium ErDivalproex Sodium | 64 | $6,280 |
| Duloxetine Hcl | 252 | $4,849 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 160 | $4,846 |
| Lamotrigine | 323 | $4,543 |
| Quetiapine Fumarate | 286 | $4,452 |
| Clonazepam | 470 | $4,356 |
| Bupropion XlBupropion Hcl | 203 | $4,297 |
| Thiothixene | 31 | $3,794 |
| Aripiprazole | 166 | $3,690 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $99 | $39,34926 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse, Trintellix | $206 | $37,70675 claims |
| Almatica Pharma LLCSertraline Hcl | $45 | $1,348155 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 543 psychiatry providers in Wisconsin.
Other psychiatry in Milwaukee
- Thomas IlicMilwaukee$324K
- Jay WinstonMilwaukee$238K
- Joseph BurgarinoMilwaukee$111K
- Jacob BehrensMilwaukee$94K
- Selahattin KurterMilwaukee$17K
- Harold HarschMilwaukee$8K
- Ajay SehgalMilwaukee$7K
- Edgar JacksonMilwaukee$5K
- Ali ArtarMilwaukee$5K
- Robert RuskiewiczMilwaukee$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.